Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
T DemirerW I Bensinger

Abstract

Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer. PBSCs were collected from 17 patients with breast (n = 11), ovarian (n = 5), and gastric (n = 1) cancer after administration of Taxol (170 mg/m2 x 1) and CY (4 g/m2 x 1) followed by rhG-CSF (10 micrograms/kg/d). PBSC collections after Taxol and CY were compared with PBSC collections from nine patients with stage IV breast (n = 8) or stage III ovarian (n = 1) cancer who had received CY (4 g/m2 x 1) followed by rhG-CSF (16 micrograms/kg/d) for mobilization. Mean WBC and platelet counts on the first day of apheresis were 6.3 x 10(9)/L (range, 1.9 to 22.1) and 35 x 10(9)/L (range, 19 to 77), respectively. The median numbers of CD34+ cells, peripheral-blood mononuclear cells (PBMNC), and peripheral-blood total nucleated cells (PBTNC) collected were 13.02 x 10(6)/kg (range, 5.4 to 57.8; mean, 16.02), 6.86 x 10(8)/kg (range, 1.9 to 51.2), and 17.41 x 10(8)/kg (range, 2.4 to 106.6), respectively. In the comparison group, the media...Continue Reading

Citations

Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H. KurataK. Tanaka
Apr 21, 2004·Annals of Plastic Surgery·Jeffrey S IsenbergJohn O Ojeifo
Sep 30, 2000·Stem Cells·R K ShadduckJ Lister
Jun 1, 1999·Journal of Hematotherapy·T DemirerC D Buckner
Jun 14, 2003·Journal of Hematotherapy & Stem Cell Research·John O OjeifoKenneth R Meehan
Jan 1, 1996·Stem Cells·T DemirerW I Bensinger
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Kenneth R MeehanMarc E Lippman
Nov 9, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Taner DemirerHamdi Akan
May 26, 1998·Environmental Health Perspectives·R E Parchment

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
B S ReichmanC A Hudis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J H SchillerD Spriggs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D S SonnichsenM V Relling
© 2021 Meta ULC. All rights reserved